Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock
Recruiting
Phase 2
Interventional Study
Septic Shock
Sepsis
Pathologic Processes
Shock
Systemic Inflammatory Response Syndrome
Inflammation
Infections
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 296 (estimated)
- Sponsor
- Ottawa Hospital Research Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated MSCs in patients wit…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
A participant must meet all the following inclusion criteria at time of randomization to be eligible:
1. At least 18 years of age AND
2. Requirement for admission to the intensive care unit AND
3. Index admission to the intensive care unit AND
4. Cardiovascular organ failure fo…
Contacts